当前位置: X-MOL 学术J. Appl. Physiol. Cell Physiol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Spatial locations of certain enzymes and transporters within pre-invasive ductal epithelial cells predict human breast cancer recurrences.
American Journal of Physiology-Cell Physiology ( IF 5.5 ) Pub Date : 2020-09-09 , DOI: 10.1152/ajpcell.00280.2020
Alexandra M Kraft 1 , Howard R Petty 1
Affiliation  

Some patients treated for ductal carcinoma in situ (DCIS) of the breast will experience cancer recurrences, whereas other patients will not. Unfortunately, current techniques cannot identify which pre-invasive lesions will lead to recurrent cancer. Because the mechanism of cancer recurrence is unknown, it is difficult to design a test that detects its activity. We propose that certain pentose phosphate pathway enzymes, glutathione synthesis enzymes, and RhoA cluster at the epithelial cell periphery during cancer recurrences. Enzyme clustering enhances metabolic flux. Using fluorescence microscopy we show that phosphophorylated glucose transporter type-1, transketolase-like protein-1, glutathione synthetase, GTP-loaded RhoA, and RhoA accumulate at the epithelial cell periphery in biopsies of women who will suffer recurrences, but not in samples from women who will not experience recurrences as judged using 2x2 contingency tables. A machine study of individual cribriform, papillary, micropapillary, and comedo forms of DCIS demonstrated 97% precision and 95% recall in the detection of samples from women will not experience a recurrence and a 90% precision and 95% recall in the detection of lesions that become recurrent. A holdout study of these patients showed 73% true negatives, 18% true positives, 4% false positives, and 4% false negatives at a 50% threshold. This work suggests mechanistic features of recurrences that may contribute to a new clinical test distinguishing high from low recurrence risk DCIS patients.

中文翻译:

浸润前导管上皮细胞内某些酶和转运蛋白的空间位置预示着人类乳腺癌的复发。

一些接受过乳腺导管原位癌(DCIS)治疗的患者会复发,而其他患者则不会。不幸的是,当前的技术无法确定哪些浸润前病变会导致癌症复发。由于癌症复发的机制尚不清楚,因此难以设计检测其活性的测试。我们提出在癌症复发期间某些戊糖磷酸途径酶,谷胱甘肽合成酶和RhoA聚集在上皮细胞周围。酶聚集增强了代谢通量。使用荧光显微镜,我们发现磷酸化的葡萄糖转运蛋白1型,转酮醇酶样蛋白1,谷胱甘肽合成酶,GTP加载的RhoA和RhoA积累在将要复发的妇女的活检组织中的上皮细胞外围,但不是来自使用2x2列联表判断不会复发的女性样本中。对DCIS的各种筛状,乳头状,微乳头状和粉刺状的机器研究表明,从女性样本中检测出97%的准确度和95%的召回率不会复发,在检测病灶中有90%的准确度和95%的召回率变得复发。对这些患者的坚持研究显示,在50%的阈值下,真实阴性73%,真实阳性18%,假阳性4%和假阴性4%。这项工作表明了复发的机制特征,这可能有助于区分高复发风险和低复发风险的DCIS患者的新临床试验。DCIS和粉刺形式的DCIS证明,从女性样本中检测出97%的准确度和95%的召回率不会复发,而在检测到复发的病变中则具有90%的准确度和95%的召回率。对这些患者的坚持研究显示,在50%的阈值下,真实阴性73%,真实阳性18%,假阳性4%和假阴性4%。这项工作表明了复发的机制特征,这可能有助于区分高复发风险和低复发风险的DCIS患者的新临床试验。DCIS和粉刺形式的DCIS证明,从女性样本中检测出97%的准确度和95%的召回率不会复发,而在检测到复发的病变中则具有90%的准确度和95%的召回率。对这些患者的坚持研究显示,在50%的阈值下,真实阴性73%,真实阳性18%,假阳性4%和假阴性4%。这项工作表明了复发的机制特征,这可能有助于区分高复发风险和低复发风险的DCIS患者的新临床试验。以及在50%的阈值下有4%的假阴性。这项工作表明了复发的机制特征,这可能有助于区分高复发风险和低复发风险的DCIS患者的新临床试验。以及在50%的阈值下有4%的假阴性。这项工作表明了复发的机械特征,这可能有助于区分高复发风险和低复发DCIS患者的新临床试验。
更新日期:2020-09-10
down
wechat
bug